IRF-5 Is a Mediator of the Death Receptor-induced Apoptotic Signaling Pathway*
暂无分享,去创建一个
[1] T. Taniguchi,et al. A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis , 2008, Proceedings of the National Academy of Sciences.
[2] G. Jaffe,et al. Caspase-8-mediated apoptosis in human RPE cells. , 2007, Investigative ophthalmology & visual science.
[3] K. Honda,et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression , 2007, Proceedings of the National Academy of Sciences.
[4] D. Lawrence,et al. Molecular Determinants of Kinase Pathway Activation by Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand* , 2005, Journal of Biological Chemistry.
[5] B. Barnes,et al. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. , 2005, Cancer research.
[6] S. Gibson,et al. Transcription Factor NF-κB Differentially Regulates Death Receptor 5 Expression Involving Histone Deacetylase 1 , 2005, Molecular and Cellular Biology.
[7] A. Karpova,et al. Identification of TRAIL as an Interferon Regulatory Factor 3 Transcriptional Target , 2005, Journal of Virology.
[8] Katherine E. M. Hoops,et al. Two Discrete Promoters Regulate the Alternatively Spliced Human Interferon Regulatory Factor-5 Isoforms , 2005, Journal of Biological Chemistry.
[9] R. Zeillinger,et al. Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer , 2005, Molecular Cancer Research.
[10] D. Golenbock,et al. The Interferon Regulatory Factor, IRF5, Is a Central Mediator of Toll-like Receptor 7 Signaling* , 2005, Journal of Biological Chemistry.
[11] J. Houghton,et al. Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines , 2005, Oncogene.
[12] Tak W. Mak,et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors , 2005, Nature.
[13] S. Lowe,et al. DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis , 2005, Molecular and Cellular Biology.
[14] J. Hiscott,et al. A CRM1-dependent Nuclear Export Pathway Is Involved in the Regulation of IRF-5 Subcellular Localization* , 2005, Journal of Biological Chemistry.
[15] G. Barber,et al. A FADD-dependent innate immune mechanism in mammalian cells , 2004, Nature.
[16] Q. Deveraux,et al. Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. , 2004, Molecular biology of the cell.
[17] S. Hanash,et al. Global and Distinct Targets of IRF-5 and IRF-7 during Innate Response to Viral Infection* , 2004, Journal of Biological Chemistry.
[18] W. El-Deiry,et al. Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity , 2004, Molecular and Cellular Biology.
[19] H. Gronemeyer,et al. Tumor suppressor IRF‐1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL , 2004, The EMBO journal.
[20] A. Ashkenazi,et al. Targeting death receptors in cancer with Apo2L/TRAIL. , 2004, Current opinion in pharmacology.
[21] W. Winkelmann,et al. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells , 2003, International journal of cancer.
[22] P. Pitha,et al. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. , 2003, Cancer research.
[23] Hideo Negishi,et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence , 2003, Nature.
[24] K. Eguchi,et al. Interferon-α sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-κB inactivation , 2003, Oncogene.
[25] P. Pitha,et al. Multiple Regulatory Domains of IRF-5 Control Activation, Cellular Localization, and Induction of Chemokines That Mediate Recruitment of T Lymphocytes , 2002, Molecular and Cellular Biology.
[26] H. Döhner,et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. , 2002, Blood.
[27] Yusuke Nakamura,et al. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53 , 2002, Oncogene.
[28] Tatsushi Yoshida,et al. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL‐R2 gene1 , 2001, FEBS letters.
[29] T. Taniguchi,et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN–α/β , 2001, European journal of immunology.
[30] P. Moore,et al. Virus-specific Activation of a Novel Interferon Regulatory Factor, IRF-5, Results in the Induction of Distinct Interferon α Genes* , 2001, The Journal of Biological Chemistry.
[31] T. Taniguchi,et al. The interferon system and interferon regulatory factor transcription factors -- studies from gene knockout mice. , 2001, Cytokine & growth factor reviews.
[32] R. K Srivastava,et al. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways , 2001, Oncogene.
[33] A. Winoto,et al. FADD Is Required for DR4- and DR5-mediated Apoptosis , 2000, The Journal of Biological Chemistry.
[34] W. El-Deiry,et al. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.
[35] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.
[36] J. Beckmann,et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. , 1998, Immunity.
[37] D. Goeddel,et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. , 1998, Science.
[38] S. Ferrini,et al. Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon-sensitive response element (ISRE) , 2004, Cell Death and Differentiation.